Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

While you are sipping a beverage by the fire over the holidays, why not read the latest Hot Student Paper? This week's top honours go to former ROP student Nicole Tillie working with Prof. Jayson Parker, who recently published “Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action" in the Canadian Journal of Gastroenterology and Hepatology. In this study Nicole quantified the risk that new drug candidates for this disease fail clinical testing and never reach the market.  She found that only 20% of drugs succeed during clinical testing with small drug viral inhibitors being the most successful. Nicole is now studying at the Canadian College of Naturopathic medicine. Congratulations on your success!